Clariane SE

ENXTPA:CLARI Stock Report

Market Cap: €634.3m

Clariane Valuation

Is CLARI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLARI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLARI (€1.75) is trading below our estimate of fair value (€21.9)

Significantly Below Fair Value: CLARI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLARI?

Key metric: As CLARI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CLARI. This is calculated by dividing CLARI's market cap by their current revenue.
What is CLARI's PS Ratio?
PS Ratio0.1x
Sales€5.17b
Market Cap€634.27m

Price to Sales Ratio vs Peers

How does CLARI's PS Ratio compare to its peers?

The above table shows the PS ratio for CLARI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
EMEIS emeis Société anonyme
0.2x6.5%€839.3m
GDS Ramsay Générale de Santé
0.3xn/a€1.3b
LNA LNA Santé
0.3x8.9%€242.3m
EQS Equasens Société anonyme
2.8x6.7%€611.8m
CLARI Clariane
0.1x4.9%€624.0m

Price-To-Sales vs Peers: CLARI is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does CLARI's PS Ratio compare vs other companies in the European Healthcare Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.0.6x5.1%
CLARI Clariane
 0.1x4.9%US$654.04m
CLARI 0.1xIndustry Avg. 0.6xNo. of Companies13PS00.61.21.82.43+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.0.6x24.8%
CLARI Clariane
 0.1x112.0%US$654.04m
No more companies

Price-To-Sales vs Industry: CLARI is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is CLARI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLARI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: CLARI is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLARI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.75
€2.04
+16.4%
12.6%€2.40€1.70n/a5
Nov ’25€2.05
€1.95
-5.1%
10.6%€2.20€1.70n/a4
Oct ’25€1.69
€1.95
+15.1%
10.6%€2.20€1.70n/a4
Sep ’25€1.93
€1.95
+0.9%
10.6%€2.20€1.70n/a4
Aug ’25€1.78
€2.35
+32.1%
6.4%€2.50€2.20n/a2
Jul ’25€1.85
€5.20
+180.8%
51.9%€7.90€2.50n/a2
Jun ’25€3.22
€3.83
+18.9%
63.1%€7.90€1.70n/a4
May ’25€2.25
€3.83
+70.0%
63.1%€7.90€1.70n/a4
Apr ’25€1.47
€4.50
+205.3%
56.6%€7.90€1.70n/a5
Mar ’25€1.90
€4.53
+137.9%
48.0%€7.90€2.50n/a6
Feb ’25€2.20
€5.31
+141.0%
52.3%€10.00€2.50n/a7
Jan ’25€2.40
€5.31
+120.8%
52.3%€10.00€2.50n/a7
Dec ’24€2.19
€6.14
+180.5%
43.7%€10.00€2.80n/a7
Nov ’24€3.61
€8.61
+138.2%
30.6%€12.00€5.00€2.057
Oct ’24€5.70
€10.44
+83.1%
18.6%€13.00€7.20€1.697
Sep ’24€6.27
€10.44
+66.4%
18.6%€13.00€7.20€1.937
Aug ’24€6.74
€11.48
+70.4%
25.5%€17.00€7.50€1.787
Jul ’24€6.66
€11.69
+75.6%
24.8%€17.00€7.50€1.857
Jun ’24€7.12
€11.69
+64.3%
24.8%€17.00€7.50€3.227
May ’24€7.86
€11.69
+48.9%
24.8%€17.00€7.50€2.257
Apr ’24€6.89
€15.31
+122.2%
54.6%€36.00€7.50€1.478
Mar ’24€7.35
€21.31
+190.0%
38.4%€36.00€9.00€1.908
Feb ’24€9.45
€23.56
+149.5%
35.0%€36.00€10.50€2.208
Jan ’24€10.12
€24.69
+143.9%
28.3%€36.00€14.00€2.408
Dec ’23€9.62
€24.69
+156.6%
28.3%€36.00€14.00€2.198
Nov ’23€10.21
€25.94
+154.0%
27.4%€36.00€14.00€3.618

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Equasens Société anonyme

€625.3m

Provides healthcare IT solutions in Europe.

EQS

€40.70

7D

-7.1%

1Y

-29.1%

Laboratoires Euromedis Société anonyme

€13.0m

Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.

ALEMG

€4.57

7D

-3.6%

1Y

-4.2%

emeis Société anonyme

€901.5m

Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.

EMEIS

€5.21

7D

-10.7%

1Y

-98.3%